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Background:  Little is known about the association between bleeding and death, and in particular, the actual cause of death, in patients on 
different antiplatelet agents. We therefore sought to investigate the association between bleeding and mortality subtype, and assess whether this 
association differs in patients on dual antiplatelet therapy (DAPT) versus aspirin alone.
Methods:  Using multivariable Cox proportional-hazards modeling, we examined the association between moderate or severe bleeding and all-
cause, cardiovascular, and cancer mortality in 15,603 patients with cardiovascular disease or multiple risk factors enrolled in the Clopidogrel for 
High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Results:  Patients with moderate or severe bleeding had a higher incidence of all-cause, cardiovascular, and cancer mortality (P<0.001 for each). 
After multivariable adjustment, moderate/severe bleeding remained independently associated with not only all-cause mortality (adjusted hazard 
ratio [HR], 1.66; 95% confidence interval [CI], 1.24-2.21) and cardiovascular mortality (HR, 2.05; 95% CI, 1.38-3.04), but cancer mortality as 
well (HR, 4.76; 95% CI, 2.60-8.69). However, there was a significant interaction between bleeding and potency of antiplatelet therapy for all-cause 
(P=0.002), cardiovascular (P=0.02), and cancer mortality (P=0.03); in subjects on aspirin alone, moderate/severe bleeding was associated with 
all-cause (HR, 5.27; 95% CI, 3.56-7.80), cardiovascular (HR, 4.33; 95% CI, 2.55-7.37), and cancer mortality (HR, 9.01; 95% CI, 4.41-18.43), but not 
in subjects on DAPT (all-cause - [HR, 1.48; 95% CI, 0.93-2.34], cardiovascular- [HR, 1.04; 95% CI, 0.58-1.86] and cancer mortality [HR, 1.79; 95% 
CI, 0.56-5.74]).
Conclusions:  In stable patients, moderate or severe bleeding is associated with a significantly increased risk of all-cause, cardiovascular, and 
cancer mortality. However, this risk differed in subjects on aspirin alone versus DAPT.
